Malignant Peripheral Nerve Sheath Tumor of Non-Neurofibromatosis Type I Metastasized to the Cerebrospinal Axis

Man-Kyu Park, M.D., Joo-Kyung Sung, M.D., Ph.D., Kyung-Hun Nam, M.D., Kyoung-Tae Kim, M.D.
Department of Neurosurgery, Kyungpook National University Hospital, Daegu, Korea

A malignant peripheral nerve sheath tumor (MPNST) is a type of sarcoma that arises from peripheral nerves or cells of the associated nerve sheath. This tumor most commonly metastasizes to the lung and metastases to the spinal cord and brain are very rare. We describe a case of young patient with spinal cord and brain metastases resulting from MPNST. An 18-year-old man presented with a 6-month history of low back pain and radiating pain to his anterior thigh. Magnetic resonance imaging showed a paraspinal mass that extended from the central space of L2 to right psoas muscle through the right L2-3 foraminal space. The patient underwent surgery and the result of the histopathologic study was diagnostic for MPNST. Six months after surgery, follow-up images revealed multiple spinal cord and brain metastases. The patient was managed with chemotherapy, but died several months later. Despite complete surgical excision, the MPNST progressed rapidly and aggressively. Thus, patients with MPNST should be followed carefully to identify local recurrence or metastasis as early as possible.

Key Words : Malignant peripheral nerve sheath tumors · Brain metastasis · Spinal cord metastasis.
Spinal Cord and Brain Metastasis of MPNST in a Young Male Patient. MK Park, et al.

In adulthood typically between the ages of 20 and 50 years of age. Approximately 10-20% of cases have been reported to occur in the first 2 decades of life, with occasional cases involving infants as young as 11 months of age.

The metastatic patterns of non-NF-1 MPNST have not been well reported. Hruban et al. described 43 patients with MPNST and of these patients, 28 (65%) had distant metastasis. Sites of metastasis included the lungs (22 cases), bone (9 cases), pleura (6 cases), and brain (5 cases).

**Surgery**

The patient underwent surgery using a posterior approach. A paramedian incision was made from the L1 to L4 and we exposed the right L2 and L3 lamina with transverse process. Right L2 hemilaminectomy was performed using a high speed drill and kerrison rongeur to expose the thecal sac. For removal of intradural portion, the thecal sac was incised. The mass was soft and slightly reddish. The margin of mass was relatively distinct from neural tissue, thus gross total resection was possible under microscopic view. To remove the mass extended to the psoas muscle, the right transverse process of L2 and L3 was resected and the mass was visible. Piecemeal resection of the mass was performed and gross total resection was achieved. Frozen biopsy was reported as schwannoma.

**Postoperative course**

After the operation, his symptom had improved. However, a few days later, his confirmed pathologic report was presented as MPNST (Fig. 2). The contrast-enhanced MRI was followed at 1 month after the operation and revealed a total removal of tumor (Fig. 3). We recommended the postoperative radiotherapy for prevention of local recurrence. However, the patient declined the external beam radiation due to the fear of potential radiation risk. Six months after surgery, the patient revisited our clinic with a moderate headache. Contrast-enhanced MRI was obtained including brain and spine for workup. Spine and brain MRI showed that the tumor recurrence with leptomeningeal, multiple spinal cord and brain metastases (Fig. 4). Complete surgical clearance of the tumor was not technically feasible, owing to the multiple metastases. Therefore, the patient was referred for adjuvant chemotherapy. In addition, intrathecal chemotherapy was performed. However, no significant effect was observed and the patient's condition deteriorated gradually. After 4 months of chemotherapy, he was referred to the hospice hospital and died within a month.

**DISCUSSION**

Non-NF-1 MPNSTs are very rare and the occurrence of MPNSTs occurring in adolescents is very rare. MPNSTs generally occur in adulthood typically between the ages of 20 and 50 years of age. Approximately 10-20% of cases have been reported to occur in the first 2 decades of life, with occasional cases involving infants as young as 11 months of age.

The metastatic patterns of non-NF-1 MPNST have not been well reported. Hruban et al. described 43 patients with MPNST and of these patients, 28 (65%) had distant metastasis. Sites of metastasis included the lungs (22 cases), bone (9 cases), pleura (6 cases), and brain (5 cases).
cases), retroperitoneum (4 cases), diaphragm (3 cases), inguinal lymph nodes (2 cases), liver (2 cases), chest wall (2 cases), soft tissue (2 cases), pulmonary hilum, pericardium, thyroid gland, and adrenal gland (1 case each). Baehring et al. described 11 distant metastasises in 54 patients with MPNST that included metastases to lymph nodes, pleura, lung, liver, adrenal gland, leptomeninges and brain. William et al. reported a non-NF-1 MPNST case of metastasis to the spinal cord. Our case showed that leptomeningeal, spinal cord and brain metastasis of non-NF-1 MPNST for relatively short period after tumor removal in young male patient, reflecting aggressive nature of this malignancy.

The mainstay of treatment is surgical resection. The outcome with respect to both local recurrence and distant metastasis largely depends on grade of surgical excision. Radiation therapy combined with wide surgical excision offers statistical significant reduction in the rates of local disease recurrence. However, it has not had a meaningful reduction in either rate of distant metastasis or overall survival. Benefit of chemotherapy is unproven and its application is limited to high grade metastatic disease. Recently, the results of using adjuvant chemotherapy have been reported with limited successes. The Italian and German soft tissue sarcoma cooperative group reported an overall pediatric response rate of 45%, with the highest response noted among patients with MPNST. The 5-year survival rate has been reported to range from 40-68%. The 5-year survival rate has been reported at 16-52% and a favorable prognosis has been related with complete surgical excision of the tumors that are sized less than 5 cm. Historically, MPNSTs have been difficult tumors to treat due to their inherently aggressive nature and dismal prognosis.

Our patient underwent complete surgical excision, but the patient was not treated with radiotherapy. Follow-up images revealed multiple spinal cord and brain metastases. The patient was managed with chemotherapy, but expired several months later. Despite complete surgical excision, the MPNST progressed rapidly and aggressively.

CONCLUSION

We reported a case of MPNST that had metastasized to the brain and spinal cord. Because the MPNST showed both rapid and aggressive progression, patients should be followed carefully to identify local recurrence or metastasis and be mandatory an adjuvant radiotherapy.

References

1. Adamson DC, Cummings TJ, Friedman AH: Malignant peripheral nerve sheath tumor of the spine after radiation therapy for Hodgkin’s lymphoma. Clin Neuropathol 23:245-255, 2004
2. Amin A, Saffaddin A, Flanagan A, Patterson D, Lehosky J: Radiotherapy-induced malignant peripheral nerve sheath tumor of the cauda equina. Spine (Phila Pa 1976) 29:E506-E509, 2004
3. Baehring JM, Betensky RA, Batchelor TT: Malignant peripheral nerve sheath tumor: the clinical spectrum and outcome of treatment. Neurology 61:696-698, 2003
4. Baek WS, Pytel P, Undevia SD, Rubeiz H: Spinal cord metastasis of a non-neurofibromatosis type-1 malignant peripheral nerve sheath tumor: an unusual manifestation of a rare tumor. J Neurooncol 74:183-185, 2005
5. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Istrup DM: Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 57:2006-2021, 1986
6. Ellison DA, Corredor-Buchmann J, Parham DM, Jackson RJ: Malignant triton tumor presenting as a rectal mass in an 11-month-old. Pediatr Dev Pathol 8:235-239, 2005
7. Hruban RH, Shiu MH, Senie RT, Woodruff JM: Malignant peripheral nerve sheath tumors of the buttock and lower extremity. A study of 43 cases. Cancer 66:1253-1265, 1990
8. Kim KT, Park YS, Kwon IT, Kim YB: Primary paraspinous malignant peripheral nerve sheath tumor. J Korean Neurosurg Soc 44:91-94, 2008
9. Kinebuchi Y, Noguchi W, Igawa Y, Nishizawa O: Recurrent retropertioneal malignant nerve sheath tumor associated with neurofibromatosis type 1 responding to carboplatin and etoposide combined chemotherapy. Int J Clin Oncol 10:353-356, 2005
10. Kourea HP, Bilsly MH, Leung DH, Lewis JJ, Woodruff JM: Subdural and intrathoracic paraspinous malignant peripheral nerve sheath tumors: a clinicopathologic study of 25 patients and 26 tumors. Cancer 82:2191-2203, 1998
11. Landy H, Feun L, Markoe A, Patchen S, Bruce J, Marcus J, et al.: Extended remission of a recurrent median nerve malignant peripheral nerve sheath tumor after multimodal treatment. Case report. J Neurosurg 103:760-763, 2005
12. Masui F, Yokoyama R, Soshi S, Beppu Y, Asanuma K, Fujii K: A malignant peripheral nerve-sheath tumour responding to chemotherapy. J Bone Joint Surg Br 86:113-115, 2004
13. Weiss SW, Goldblum JR, Enzinger FM: Enzinger and Weiss’s Soft Tis-
14. Wong WW, Hirose T, Scheithauer BW, Schild SE, Gunderson LL: Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys 42: 351-360, 1998

15. Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, et al.: Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 16: 197-203, 1998